abstract
Islets of Langerhans need to maintain their round morphology and to be fast revascularized after transplantation to preserve functional insulin secretion in response to glucose stimulation. For this purpose, a non-cell-adhesive environment is preferable for their embedding. Conversely, nutrient and oxygen supply to islets is guaranteed by capillary ingrowth within the construct and this can only be achieved in a matrix that provides adhesion cues for cells. In this study, two different approaches are explored, which are both based on a layered architecture, in order to combine these two opposite requirements. A non-adhesive islet encapsulation layer is based on polyethyleneglycole diacrylate (PEGDA). This first layer is combined with a second hydrogel based on thiolated-gelatin, thiolated-heparin and thiolated-hyaluronic acid providing cues for endothelial cell adhesion and acting as a growth factor releasing matrix. In an alternative approach, a conformal PEGDA coating is covalently applied on the surface of the islets. The coated islets are subsequently embedded in the previously mentioned hydrogel containing thiolated glycosaminoglycans. The suitability of this approach as a matrix for controlled growth factor release has been demonstrated by studying the controlled release of VEGF and bFGF for 14 days. Preliminary tube formation has been quantified on the growth factor loaded hydrogels. This approach should facilitate blood vessel ingrowth towards the embedded islets and maintain islet round morphology and functionality upon implantation.
keywords
BETA-CELL FUNCTION; POLY(ETHYLENE GLYCOL) HYDROGELS; PANCREATIC-ISLETS; IN-VITRO; GROWTH-FACTOR; DIABETES-MELLITUS; EDMONTON PROTOCOL; TRANSPLANTATION; TISSUE; SURVIVAL
subject category
Engineering; Materials Science
authors
Marchioli, G; Zellner, L; Oliveira, C; Engelse, M; de Koning, E; Mano, J; Karperien; van Apeldoorn, A; Moroni, L
our authors
João Mano
Vice Directoracknowledgements
This research is part of the Diabetes Cell Therapy Initiative (DCTI) and funded by the Dutch Diabetes fund and the Ministry of economic affairs (FES program) of the Netherlands.